The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review
Authors:
- Mariana CandeiasMCMariana Candeias
- Anderson Matheus PereiraAPAnderson Matheus Pereira
- Maria BernadeteMBMaria Bernadete
- 19 December 2025
- journal article
- review article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 51 (1) , 17-28
Abstract
Background and Objective Phytocannabinoids, the main bioactive compounds of Cannabis sativa, are metabolized by hepatic cytochrome P450 (CYP450) enzymes and can also modulate their function. Since CYP450 isoforms are responsible for the metabolism of approximately 80% of therapeutic drugs, interactions between phytocannabinoids and these enzymes may have clinically relevant consequences. The objective of this systematic review was to systematically evaluate the effects of phytocannabinoids on the activity and expression of hepatic CYP450 complex enzymes. Methods This systematic review was conducted according to PRISMA guidelines. Literature searches were performed in PubMed, SciELO, ScienceDirect, and Scopus, covering studies published between January 2019 and March 2025. In vitro, in vivo, or ex vivo studies that evaluated the modulatory effects of phytocannabinoids on hepatic CYP450 isoforms were included. After applying the inclusion and exclusion criteria, four studies met the eligibility requirements. Results The selected studies reported that phytocannabinoids, particularly cannabidiol (CBD), exert inhibitory effects on several CYP450 isoforms, including CYP3A4, CYP2C9, and CYP2C19. One study indicated that CYP2C19 activity could also be induced under certain conditions. In contrast, CYP2D6 showed minimal or no modulation. Overall, CBD was consistently identified as a potent inhibitor of CYP enzymes responsible for drug metabolism. Conclusion Phytocannabinoids, particularly CBD, influence the activity of key CYP450 system enzymes, predominantly through inhibition. These findings highlight the potential for drug–cannabinoid interactions and emphasize the need for additional clinical and mechanistic studies to assess safety and pharmacokinetic implications in patients using cannabis-based therapies. Graphical AbstractKeywords
This publication has 32 references indexed in Scilit:
- Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult ParticipantsClinical Pharmacology & Therapeutics, 2023
- How does multiple substrate binding lead to substrate inhibition of CYP2D6 metabolizing dextromethorphan? A theoretical studyPhysical Chemistry Chemical Physics, 2023
- Midazolam as a Probe for Drug–Drug Interactions Mediated by CYP3A4: Homotropic Allosteric Mechanism of Site-Specific HydroxylationBiochemistry, 2021
- A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy SubjectsClinical Pharmacology in Drug Development, 2021
- Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment OutcomesClinical Pharmacokinetics, 2021
- Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical TrialClinical Pharmacology & Therapeutics, 2020
- Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activityJournal of Pharmacokinetics and Pharmacodynamics, 2020
- How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic reviewNeuroscience & Biobehavioral Reviews, 2019
- Cochrane Handbook for Systematic Reviews of Interventions2019
- A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy SubjectsClinical Pharmacology in Drug Development, 2019